symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
MIST,2.89,1.899085,96178,96476292,0,2.68-6.92,-0.1,Milestone Pharmaceuticals Inc.,USD,0001408443,CA59935V1076,59935V107,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.milestonepharma.com,"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montr√©al, Canada.",Mr. Joseph G. Oliveto M.B.A.,Healthcare,CA,39,15143360444,1111 Dr. Frederik-Philips Boulevard,Montreal,QC,H4M 2X6,5.12962,8.62962,https://financialmodelingprep.com/image-stock/MIST.png,2019-05-09,False,False,True,False,False
